I know predictions are risky, and can make one look foolish. That said, its pretty hard for me to dismiss that this stock won't be at near a $1 by the first quarter of next year, provided certain milestones are reached, such as FDA approval, good medical sales and an uplisting to a higher exchange. Then we should be talking institutional investors swooping in. Paul's phone well be ringing off the hook at that point.
Market Data 
Markets 
AI
